AstraZeneca opens R&D center in Cambridge, Massachusetts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
October 5, 2026 12:01 PM EDT$1 billion investment will grow AstraZenecas workforce in Massachusetts by over 50% and deliver next-generation medicines
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca today announced the opening of its newest global strategic research and development (R&D) center, in Kendall Square, Cambridge, Massachusetts. The new state-of-the-art facility builds on the Companys existing presence in Cambridge and Boston and places its scientists at the heart of one of the worlds most innovative life sciences ecosystems.
This press release features multimedia. View the full release here:... More



